AWRK6, a Novel GLP-1 Receptor Agonist, Attenuates Diabetes by Stimulating Insulin Secretion

Diabetes is a metabolic disorder leading to many complications. The treatment of diabetes mainly depends on hypoglycemic drugs, often with side effects, which drive us to develop novel agents. AWRK6 was a peptide developed from the antimicrobial peptide Dybowskin-2CDYa in our previous study, and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiuyu, Zhao, Chunlin, Jin, Lili, Zhang, Hanyu, Miao, Qifan, Liu, Hongsheng, Zhang, Dianbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213269/
https://www.ncbi.nlm.nih.gov/pubmed/30301245
http://dx.doi.org/10.3390/ijms19103053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213269/
https://www.ncbi.nlm.nih.gov/pubmed/30301245
http://dx.doi.org/10.3390/ijms19103053

Ejemplares similares